Armata Pharmaceuticals maintains an experienced board of directors comprising independent industry leaders, scientific experts, and corporate governance professionals. The current board includes Robin C. Kramer, who serves as the Chair of the Board; Dr. Deborah L. Birx, the Chief Executive Officer; Jules Haimovitz; Dr. Odysseas Kostas; Dr. Joseph M. Patti; Dr. Sarah J. Schlesinger; and Dr. Daniel B. Gilmer. These members bring extensive backgrounds spanning biotechnology research, clinical development, regulatory strategy, and financial management to guide the company's therapeutic pipeline.